Content about Attention-deficit hyperactivity disorder management

February 7, 2012

The Food and Drug Administration has approved a drug made by Shire for attention deficit hyperactivity disorder, the company said Tuesday.

PHILADELPHIA — The Food and Drug Administration has approved a drug made by Shire for attention deficit hyperactivity disorder, the company said Tuesday.

Shire announced the FDA approval of Vyvanse (lisdexamfetamine dimesylate) capsules as a maintenance treatment for adults with ADHD. The drug already was approved for use in children and was approved for treating ADHD in adults in 2008.

The company said the approval was based on a clinical trial that showed more ADHD patients controlling their symptoms with Vyvanse than with placebo.

October 17, 2011

Children can be diagnosed with attention deficit hyperactivity disorder as soon as 4 years old, according to new guidelines released Sunday by the American Academy of Pediatrics.

BOSTON — Children can be diagnosed with attention deficit hyperactivity disorder as soon as 4 years old, according to new guidelines released Sunday by the American Academy of Pediatrics.

February 28, 2011

The Food and Drug Administration has approved a new use for a Shire drug to treat attention deficit hyperactivity disorder, Shire said Monday.

PHILADELPHIA — The Food and Drug Administration has approved a new use for a Shire drug to treat attention deficit hyperactivity disorder, Shire said Monday.

The FDA approved Intuniv (guanfacine) as an add-on therapy for children and adolescents already taking stimulants to treat ADHD, also known as an adjunctive therapy.

The approval was based on a nine-week placebo-controlled study of the drug in which children and adolescents received it in combination with a stimulant.

January 10, 2011

Drug maker Shionogi has launched a new medication for attention deficit hyperactivity disorder, the company said Monday.

FLORHAM PARK, N.J. — Drug maker Shionogi has launched a new medication for attention deficit hyperactivity disorder, the company said Monday.

Shionogi announced the launch of Kapvay (clonidine hydrochloride), an extended-release drug for treating ADHD in children and adolescents. The company said the drug was the only ADHD treatment approved as an add-on to stimulant medications, though it can be used alone as well.

November 14, 2010

The Food and Drug Administration has approved an attention deficit hyperactivity disorder drug for use...

PHILADELPHIA — The Food and Drug Administration has approved an attention deficit hyperactivity disorder drug for use in adolescents.

British drug maker Shire announced Monday the approval of Vyvanse (lisdexamfetamine dimesylate) capsules for patients aged 13 to 17. The drug was already approved for children ages 6 years to 12 years and adults.

October 3, 2010

The Food and Drug Administration has approved a nonstimulant drug for treating attention deficit hyperactivity...

FLORHAM PARK, N.J. The Food and Drug Administration has approved a nonstimulant drug for treating attention deficit hyperactivity disorder.

 

Shionogi announced Monday the approval of Kapvay (clonidine hydrochloride), an extended-release drug for treating ADHD in children and adolescents ages 6 to 17 years. The company said Kapvay was the only formulation of clonidine hydrochloride approved for treating ADHD and the first ADHD treatment approved for use as an add-on therapy to stimulant drugs.

 

 

August 31, 2010

A generic drug maker has received regulatory approval for its version of an attention deficit...

MUMBAI, India A generic drug maker has received regulatory approval for its version of an attention deficit hyperactivity disorder treatment.

Sun Pharmaceutical Industries' subsidiary has received approval to market its generic version of Strattera (atomoxetine hydrochloride capsules), an ADHD drug for children ages 6 years and older, as well as teens and adults. Strattera is made and marketed by Eli Lilly.

Annual sales of branded and generic atomoxetine hydrochloride capsules are estimated to be more than $530 million.

August 10, 2010

The Food and Drug Administration has approved a late-stage clinical trial of a drug for...

July 6, 2010

The Food and Drug Administration has approved a drug made by Shire for treating attention...

May 20, 2010

British drug maker Shire presented late-stage clinical study data at a psychiatric meeting Friday indicating...

May 19, 2010

British drug maker Shire will present data on two attention deficit hyperactivity disorder treatments in...